Sotera Health Co. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Sotera Health Company (SHC) for the fiscal year ended December 31, 2024. Sotera is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services for the healthcare industry. The company operates through three reportable segments: Sterigenics (terminal sterilization services), Nordion (Cobalt-60 supply and gamma irradiation systems), and Nelson Labs (microbiological and analytical lab testing). As of December 31, 2024, the company operated 62 facilities worldwide with over 3,000 employees.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Net Revenues | $1,100.4 million | $1,049.3 million | +4.9% |
| Net Income (GAAP) | $44.4 million | $51.4 million | -13.6% |
| Adjusted Net Income | $198.5 million | $204.3 million | -2.9% |
| Adjusted EBITDA | $548.6 million | $528.0 million | +3.9% |
| Operating Income | $297.6 million | $276.7 million | +7.6% |
| Cash from Operating Activities | $224.2 million | ($147.7 million) | Significant Improvement |
| Total Indebtedness | $2,255.6 million | $2,260.6 million | Flat |
| Cash and Cash Equivalents | $277.2 million | $296.4 million | -6.5% |
Note: The significant improvement in operating cash flow in 2024 compared to 2023 is primarily due to the timing of large litigation settlement payments made in 2023 ($407.7 million for Illinois claims) versus 2024 ($35.0 million for Georgia claims).
Material Changes vs. Prior Period
- Revenue Growth: Driven by favorable pricing and volume/mix improvements across all segments, partially offset by unfavorable foreign currency exchange rates. Service revenues grew 4.0% and product revenues grew 10.4%.
- Debt Refinancing: In May 2024, the company refinanced its capital structure, issuing $1,509.4 million in Refinancing Term Loans and $750.0 million in 7.375% Senior Secured Notes due 2031. This resulted in a $24.2 million loss on refinancing of debt recorded in 2024.
- Interest Expense: Net interest expense increased 15.3% to $164.7 million, driven by lower favorability from interest rate derivatives and a decline in interest income.
- Segment Performance:
- Sterigenics: Revenue +4.6%; Segment Income +4.4%.
- Nordion: Revenue +8.0%; Segment Income +4.7%.
- Nelson Labs: Revenue +3.4%; Segment Income flat (+0.1%).
Guidance, Outlook, Risks, and Contingencies
Outlook and Capital Expenditures: The company expects to continue investing in facility expansions and Co-60 supply development. For 2025, approximately $46 million of capital expenditures are estimated for environmental facility enhancements to comply with evolving regulations.
Key Risks and Contingencies:
- Ethylene Oxide (EO) Litigation: The company faces ongoing tort lawsuits in California, Georgia, Illinois, and New Mexico alleging health impacts from EO emissions.
- Settlements: Paid $35.0 million in Jan 2024 to settle 79 Georgia claims. Settled 880 Illinois claims in 2023 for $407.7 million.
- Pending: Approximately 315 personal injury and 345 property devaluation claims remain pending in Georgia. 96 lawsuits remain in Illinois. A lawsuit by the New Mexico Attorney General is set for trial in July 2026.
- Insurance: Existing environmental liability insurance limits for EO claims have been fully utilized. Future settlements may exceed insurance recoveries.
- Regulatory Compliance: New EPA rules (NESHAP) require significant facility upgrades by April 2026 to reduce EO emissions. The company is investing in emission controls but notes uncertainty regarding future costs.
- Supply Chain: Reliance on a limited number of suppliers for Cobalt-60 (Co-60) and EO. Approximately 20% of long-term Co-60 supply is generated by Russian nuclear reactors, creating exposure to geopolitical sanctions and supply disruptions.
- Leverage: Significant indebtedness ($2.26 billion) limits financial flexibility. Debt covenants include a default trigger if enforceable judgments exceed the greater of $162.6 million or 30% of consolidated EBITDA.
Investor Verification Checklist
- EO Litigation Exposure: Verify the status of pending trials in Georgia and Illinois and the potential for future settlements exceeding current reserves.
- Regulatory Capital Costs: Confirm the sufficiency of the budgeted $46 million for 2025 environmental upgrades against actual EPA NESHAP compliance requirements.
- Co-60 Supply Security: Assess the impact of geopolitical tensions on the supply chain from Russian reactors and the progress of alternative sourcing initiatives.
- Debt Covenant Compliance: Monitor the company's ability to maintain financial ratios and manage potential appellate bond requirements for future litigation judgments.
- Non-GAAP Reconciliations: Review the reconciliation of Adjusted EBITDA to GAAP Net Income to understand the magnitude of recurring adjustments (e.g., share-based compensation, amortization) versus one-time items.